Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.
Future Oncol. 2014 Feb;10(2):195-209. doi: 10.2217/fon.13.177.
Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer.
PATIENTS & METHODS: This monocentric retrospective study included 652 patients who had curative surgery between 2006 and 2011 and adjuvant treatment decision-making, taking into account uPA/PAI-1 tumor levels.
uPA and PAI-1 levels were associated with classical clinicopathological parameters and adjuvant chemotherapy decision, but not with peritumoral vascular invasion (PVI; also known as peritumoral vascular emboli). HER2 overexpression, PVI and uPA/PAI-1 levels were not significantly associated with relapse-free survival in univariate analysis. In multivariate analysis, T stage, N stage and progesterone receptors were the only independent relapse-free survival predictive factors.
The absence of an association between uPA/PAI-1 and PVI allows their concomitant consideration in adjuvant treatment discussion. The overall good prognosis of patients with high uPA/PAI-1 levels might be linked to the uPA/PAI-1 predictive value and the inclusion of these parameters in adjuvant guidelines.
随着新辅助治疗方法的引入，我们希望重新评估 uPA/PAI-1 在早期乳腺癌中的预后和预测价值。
这是一项单中心回顾性研究，纳入了 2006 年至 2011 年间接受根治性手术且考虑了 uPA/PAI-1 肿瘤水平的辅助治疗决策的 652 例患者。
uPA 和 PAI-1 水平与经典的临床病理参数和辅助化疗决策相关，但与肿瘤周围血管侵犯（也称为肿瘤周围血管栓子）无关。在单因素分析中，HER2 过表达、PVI 和 uPA/PAI-1 水平与无复发生存率无显著相关性。多因素分析中，T 分期、N 分期和孕激素受体是无复发生存率的唯一独立预测因素。
uPA/PAI-1 与 PVI 之间缺乏关联，允许同时考虑它们在辅助治疗讨论中的作用。高 uPA/PAI-1 水平患者的总体预后良好可能与其预测价值有关，并且这些参数被纳入了辅助治疗指南。
